Floatz logo

Ortho Tri Cyclen

Metabolic Syndrome X

Virginia Commonwealth UniversityPhase 4 / ApprovedDormant
B
62/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
47/ 100
Competitive Position
95/ 100

Competitive context

44 Active assets in the Metabolic Syndrome X cohort.

Asset / SponsorPhaseRating
Lipitor
Seoul National University Hospital
Phase 4BBB
Topamax
All India Institute of Medical Sciences, Bhubaneswar
Phase 4BBB
Rosuvastatin
Dr. B. Catharine. Craven
Phase 4BBB
Pioglitazone
Philip Kern
Phase 4BBB
SIMVASTATIN
Jaime Daniel Mondragon
Phase 4BBB

View all 50 →

Same molecule, other indications

Ortho Tri Cyclen is also rated in:

cardiovascular disorderDormant
B
Indicative ·
61 / 100
View asset →
obesity disorderDormant
CCC
Indicative ·
52 / 100
View asset →
cystic fibrosisDormant
CC
Indicative ·
43 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →